Bioanalysis supporting disease biomarker discovery and validation

Eliminating Bottlenecks for Efficient Bioanalysis: Practices and Applications in Drug Discovery and Development

Volumn , Issue , 2014, Pages 162-181

  Blair, Ian A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DIAGNOSIS; DISEASES; MOLECULAR BIOLOGY; TUMORS;

CANCER BIOMARKERS; CLINICAL PRACTICES; DISEASE BIOMARKER; META ANALYSIS; PROSPECTIVE STUDY; RESEARCH ACTIVITIES; TUMOR REGRESSION; VALIDATION STUDY;

BIOMARKERS;

EID: 84942858161     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4155/FSEB.2013.13.3     Document Type: Chapter

References (45)

1. Pavlou MP, Diamandis EP, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. Clin. Chem. 59(1), 147-157 (2013).
2. Wehr AY, Hwang WT, Blair IA, Yu KH. Relative quantification of serum proteins from pancreatic ductal adeno- carcinoma patients by stable isotope dilution liquid chromatography-mass spectrometry. J. Proteome Res. 11(3), 1749-1758 (2012).
3. Ciccimaro E, Blair IA. Stable- isotope dilution LC-MS for quantitative biomarker ana- lysis. Bioanalysis 2(2), 311-341 (2010).
4. Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20(24), 3723-3735 (2006).
5. Rangiah K, Shah SJ, Vachani A, Ciccimaro E, Blair IA. Liquid chromatography/mass spectrometry of pre-ionized Girard P derivatives for quantifying estrone and its metabolites in serum from postmenopausal women. Rapid Commun. Mass Spectrom. 25(9), 1297-1307 (2011).
6. Jian W, Edom R, Weng N, Zannikos P, Zhang Z, Wang H. Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878(20), 1687-1699 (2010).
7. Mesaros C, Arora JS, Wholer A, Vachani A, Blair IA. 8-Oxo- 2-deoxyguanosine as a biomarker of tobacco- smoking-induced oxidative stress. Free Radic. Biol. Med. 53(3), 610-617 (2012).
8. Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P et al. Development, validation and application of a stable isotope dilution liquid chromatography/ selected reaction monitoring/mass spectrometry (SID-LC/ESI/ SRM/MS) method for quantification of keto- androgens in human serum. J. Steroid Biochem. Mol. Biol. 138, 281-289 (2013).
9. Blair IA. Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids 75(4-5), 297-306 (2010).
10. Basu SS, Blair IA. SILEC: a protocol for generating and using isotopically labeled coenzyme A mass spectrometry standards. Nat. Protoc. 7(1), 1-12 (2012).
11. Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry- based approaches: current strategies for candidate verification. Clin. Chem. 56(2), 212-222 (2010).
12. Yan Y, Weaver VM, Blair IA. Analysis of protein expression during oxidative stress in breast epithelial cells using a stable isotope labeled proteome internal standard. J. Proteome Res. 4(6), 2007-2014 (2005).
13. Hoofnagle AN, Becker JO, Oda MN, Cavigiolio G, Mayer P, Vaisar T. Multiple- reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin. Chem. 58(4), 777-781 (2012).
14. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27(7), 633-641 (2009).
15. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 3(2), 235-244 (2004).
16. Razavi M, Frick LE, LaMarr WA, Pope ME, Miller CA, Anderson NL et al. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J. Proteome Res. 11(12), 5642-5649 (2012).
17. Razavi M, Johnson LD, Lum JJ, Kruppa G, Anderson NL, Pearson TW. Quantification of a proteotypic peptide from protein c inhibitor by liquid chromatography-free SISCAPA-MALDI mass spectrometry: application to identification of recurrence of prostate cancer. Clin. Chem. (2013).
18. Yassine H, Borges CR, Schaab MR, Billheimer D, Stump C, Reaven P et al. Mass spectrometric immunoassay and MRM as targeted MS- based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin. Appl. 7(7-8), 528-540 (2013).
19. Jian W, Edom RW, Wang D, Weng N, Zhang SW. Relative quantitation of glycoisoforms of intact apolipoprotein C3 in human plasma by liquid chromatography-high- resolution mass spectrometry. Anal. Chem. 85(5), 2867-2874 (2013).
20. Poste G. Bring on the biomarkers. Nature 469(7329), 156-157 (2011).
21. Issaq HJ, Waybright TJ, Veenstra TD. Cancer biomarker discovery: opportunities and pitfalls in analytical methods. Electrophoresis 32(9), 967-975 (2011).
22. Zharikov S, Shiva S. Platelet mitochondrial function: from regulation of thrombosis to biomarker of disease. Biochem. Soc. Trans. 41(1), 118-123 (2013).
23. Selak MA, Lyver E, Micklow E, Deutsch EC, Onder O, Selamoglu N et al. Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion. 11(2), 342-350 (2011).
24. Shrivastava M, Das TK, Behari M, Pati U, Vivekanandhan S. Ultrastructural variations in platelets and platelet mitochondria: a novel feature in amyotrophic lateral sclerosis. Ultrastruct. Pathol. 35(2), 52-59 (2011).
25. 25 Basu SS, Blair IA. Rotenone- mediated changes in intracellular coenzyme A thioester levels: implications for mitochondrial dysfuncti n. Chem. Res. Toxicol. 24(10), 1630-1632 (2011).
26. Susiarjo M, Sasson I, Mesaros C, Bartolomei MS. Bisphenol a exposure disrupts genomic imprinting in the mouse. PLoS Genet. 9(4), e1003401 (2013).
27. Yocum AK, Yu K, Oe T, Blair IA. Effect of immunoaffinity depletion of human serum during proteomic investigations. J. Proteome Res. 4(5), 1722-1731 (2005).
28. 28 Ong SE, Mann M. Stable isotope labeling by amino acids in cell culture for quantitative proteomics. Methods Mol. Biol. 359), 37-52 (2007).
29. MacDonald ML, Ciccimaro E, Prakash A, Banerjee A, Seeholzer SH, Blair IA et al. Biochemical fractionation and stable isotope dilution liquid chromatography-mass spectrometry for targeted and microdomain-specific protein quantification in human postmortem brainti sue. Mol. Cell Proteomics 11(12), 1670-1681 (2012).
30. Treumann A, Thiede B. Isobaric protein and peptide quantification: perspectives and issues. Expert. Rev. Proteomics 7(5), 647-653 (2010).
31. Evans C, Noirel J, Ow SY, Salim M, Pereira-Medrano AG, Couto N et al. An insight into iTRAQ: where do we stand now? Anal. Bioanal. Chem. 404(4), 1011-1027 (2012).
32. Plumb RS, Johnson KA, Rainville P, Smith BW, Wilson ID, Castro-Perez JM et al. UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun. Mass Spectrom. 20(13), 1989-1994 (2006).
33. Villicana P, Whiting B, Goodison S, Rosser CJ. Urine- based assays for the detection of bladder cancer. Biomark. Med. 3(3), 265 (2009).
34. Vegvari A, Welinder C, Lindberg H, Fehniger TE, Marko-Varga G. Biobank resources for future patient care: developments, principles and concepts J. Clin. Bioinforma. 1(1), 24 (2011).
35. 35 Watts G. UK Biobank opens it data vaults to researchers. Br. Med. J. 344, e2459 (2012).
36. Betsou F, Gunter E, Clements J, DeSouza Y, Goddard KA, Guadagni F et al. Identification of evidence- based biospecimen quality- control tools: a report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group. J. Mol. Diagn. 15(1), 3-16 (2013).
37. Kang HJ, Jeon SY, Park JS, Yun JY, Kil HN, Hong WK et al. Identification of clinical biomarkers for pre-analytical quality control of blood samples. Biopreserv. Biobank. 11(2), 94-100 (2013).
38. 38 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 217(5), 483-491 (2012).
39. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J. Clin. Oncol. 28(4), 698-704 (2010).
40. Gerlach H, Toussaint S. Sensitive, specific, predictive. statistical basics: how to use biomarkers. Crit. Care Clin. 27(2), 215-227 (2011).
41. Grund B, Sabin C. Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves. Curr. Opin. HIV. AIDS 5(6), 473-479 (2010).
42. Perlis RH. Translating biomarkers to clinical practice. Mol. Psychiatry 16(11), 1076-1087 (2011).
43. Anderson NL, Ptolemy AS, Rifai N. The riddle of protein diagnostics: future bleak or bright? Clin. Chem. 59(1), 194-197 (2013).
44. Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 305(21), 2200-2210 (2011).
45. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y et al. HMDB 3.0 - the Human Metabolome Database in 2013. Nucleic Acids Res. 41(Database issue), D801-D807 (2013).